After cutbacks, Biogen adds new drug with $7.3bn Reata buy

Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma.

FDA advisors unconvinced by Reata's kidney disease drug

An FDA advisory committee has delivered a blow to Reata Pharma, after voting unanimously that the drugmaker's data on bardoxolone – a drug for kidney disease – did not show it is effective.

Reata rockets on data for Nrf2 drug reacquired from AbbVie